| Literature DB >> 29852524 |
Desiree Pressnitz1, Eva-Maria Fischereder1, Jakob Pletz1, Christina Kofler1, Lucas Hammerer1,2, Katharina Hiebler1, Horst Lechner1, Nina Richter2, Elisabeth Eger1, Wolfgang Kroutil1.
Abstract
Stereoselective methods for the synthesis of tetrahydro-ß-carbolines are of significant interest due to the broad spectrum of biological activity of the target molecules. In the plant kingdom, strictosidine synthases catalyze the C-C coupling through a Pictet-Spengler reaction of tryptamine and secologanin to exclusively form the (S)-configured tetrahydro-ß-carboline (S)-strictosidine. Investigating the biocatalytic Pictet-Spengler reaction of tryptamine with small-molecular-weight aliphatic aldehydes revealed that the strictosidine synthases give unexpectedly access to the (R)-configured product. Developing an efficient expression method for the enzyme allowed the preparative transformation of various aldehydes, giving the products with up to >98 % ee. With this tool in hand, a chemoenzymatic two-step synthesis of (R)-harmicine was achieved, giving (R)-harmicine in 67 % overall yield in optically pure form.Entities:
Keywords: Pictet-Spengler reaction; asymmetric catalysis; biocatalysis; strictosidine Synthases; tetrahydro-β-carbolines
Mesh:
Substances:
Year: 2018 PMID: 29852524 PMCID: PMC6146909 DOI: 10.1002/anie.201803372
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Scheme 1Strictosidine‐synthase‐catalyzed natural Pictet–Spengler condensation of tryptamine 1 and secologanin to give (S)‐strictosidine.
Scheme 2Strictosidine‐synthase‐catalyzed Pictet–Spengler reaction between tryptamine and non‐natural aliphatic low‐molecular‐weight aldehydes.
Biocatalytic Pictet–Spengler reaction of tryptamine 1 and non‐natural aldehydes 2.
| Entry | Aldehyde 2 | STR | Conv. [%][a] |
|
|---|---|---|---|---|
| 1 | 2 a | CrSTR | 12 | 88 ( |
| 2 | 2 a | RvSTR | 50 | >98 ( |
| 3 | 2 a | RsSTR | 77 | >98 ( |
| 4 | 2 a | OpSTR | 63 | >98 ( |
| 5 | 2 b | CrSTR | 7 | 61 ( |
| 6 | 2 b | RvSTR | 45 | 91 ( |
| 7 | 2 b | RsSTR | 42 | 87 ( |
| 8 | 2 b | OpSTR | 22 | 88 ( |
| 9 | 2 c | CrSTR | 14 |
|
| 10 | 2 c | RvSTR | 23 | 43 ( |
| 11 | 2 c | RsSTR | 38 |
|
| 12 | 2 c | OpSTR | 19 | 28 ( |
| 13 | 2 d | CrSTR | 4 | 46 ( |
| 14 | 2 d | RvSTR | 7 | 82 ( |
| 15 | 2 d | RsSTR | 7 | 79 ( |
| 16 | 2 d | OpSTR | 8 | 77 ( |
| 17 | 2 e | CrSTR | 11 | >98 ( |
| 18 | 2 e | RvSTR | 66 | >98 ( |
| 19 | 2 e | RsSTR | 95 | >98 ( |
| 20 | 2 e | OpSTR | 71 | >98 ( |
[a] Reaction conditions: tryptamine*HCl 1 (10 mm), aldehyde 2 (2 a,b,d: 50 mm, 2 c: 125 mm), freeze‐dried cell‐free extract of His6‐STR/Shuffle T7LysY (2.5 Ustrictosidine), PIPES buffer (0.5 mL, 50 mm, pH 6.1), 35 °C, 650 rpm, 20 h. Product formation and conversion were determined by GC (HP‐5 column). [b] ee was determined by HPLC with a chiral stationary phase (3 a–d: Chiralpak IC; 4: Chiralcel OD‐H).
Scheme 3Chemoenzymatic synthesis of (R)‐harmicine in two steps starting from commercial substrates.